Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
A committee to be formed to suggest measures for ensuring the safety of healthcare professionals
The emergence of new infections in India is a growing concern
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
This two-day program was attended by 40 doctors & paramedical staff
Subscribe To Our Newsletter & Stay Updated